BuildGene Co., Ltd. is a biotechnology innovator developing next-generation peptide synthesis and delivery platforms. Our NeoPepX™ platform enables efficient, cost-competitive cell-free production of peptides and proteins incorporating non-canonical amino acids (ncAAs). Complementing this, the SENP™ self-emulsifying nanoparticle technology ensures stable and targeted delivery via transdermal, mucosal, oral, and injectable routes. Leveraging these platforms, HUIS builds pipelines spanning cosmeceuticals, OTC products, and novel therapeutics, while pursuing licensing, CDMO partnerships, and global tech transfer. Combining scientific expertise with business execution, HUIS aims to become a global bio-platform leader advancing health and quality of life.

PHDP™ (Peptide Hybrid Design Platform) uses AI- and DoE-driven design to create functional peptides in diverse formats?linear, cyclic, acylated, ncAA- or D-AA?modified?targeting whitening, anti-inflammatory, neuroprotective, and metabolic applications. NeoPepX™ is a cell-free synthesis platform that integrates immobilized enzyme cartridges and AI-controlled continuous reactors to cost-effectively produce peptides and proteins with site-specific non-canonical amino acid incorporation, enabling scalability beyond chemical synthesis. NeoSENP™ is a self-emulsifying nanoparticle delivery platform that layers polyelectrolyte complexes (chitosan, hyaluronic acid) with SES oil coatings to achieve stable, controlled delivery across skin, mucosal, oral, and injectable routes. Together, these plat